Renal osteodystrophy: new developments and challenges

Vincent Boima; Josephine Akpalu; Akosua Asomaning

doi:10.1016/B978-0-443-33090-2.00019-9

Renal osteodystrophy: new developments and challenges

Vincent Boima
, Josephine Akpalu
, Akosua Asomaning

Department of Medicine And Therapeutics

Korle Bu Teaching Hospital

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Renal osteodystrophy is a bone ailment associated with or worsened by chronic kidney disease (CKD), resulting in fractures and further problems. CKD-mineral bone disorder (CKD-MBD) is a widely recognized term that characterizes a comprehensive systemic mineral and bone metabolism condition. Recent investigations have elucidated the involvement of several new variables in the pathophysiology of CKD-MBD, including wingless and integration 1 (Wnt) inhibitors, activin A, and myostatin. A bone biopsy is the definitive method for identifying CKD-MBD, whereas biomarkers like parathyroid hormone, calcium, phosphorus, alkaline phosphatase, and radiological imaging are advised for initial assessment. Innovative strategies for managing CKD-MBD designed to enhance outcomes have been established.

Original language	English
Title of host publication	RENAL FAILURE
Subtitle of host publication	Insights from Nephrotic Syndrome to Systemic Renal Dynamics
Publisher	Elsevier
Pages	255-289
Number of pages	35
ISBN (Electronic)	9780443330902
ISBN (Print)	9780443330919
DOIs	https://doi.org/10.1016/B978-0-443-33090-2.00019-9
Publication status	Published - 1 Jan 2025

Keywords

Mineral bone disorder
calcium
imaging
novel therapy
osteodystrophy
parathyroid hormone
pathogenesis
phosphates
vitamin D

Access to Document

10.1016/B978-0-443-33090-2.00019-9

Cite this

@inbook{4129c4cf9103475a98312ebcbdf90e17,

title = "Renal osteodystrophy: new developments and challenges",

abstract = "Renal osteodystrophy is a bone ailment associated with or worsened by chronic kidney disease (CKD), resulting in fractures and further problems. CKD-mineral bone disorder (CKD-MBD) is a widely recognized term that characterizes a comprehensive systemic mineral and bone metabolism condition. Recent investigations have elucidated the involvement of several new variables in the pathophysiology of CKD-MBD, including wingless and integration 1 (Wnt) inhibitors, activin A, and myostatin. A bone biopsy is the definitive method for identifying CKD-MBD, whereas biomarkers like parathyroid hormone, calcium, phosphorus, alkaline phosphatase, and radiological imaging are advised for initial assessment. Innovative strategies for managing CKD-MBD designed to enhance outcomes have been established.",

keywords = "Mineral bone disorder, calcium, imaging, novel therapy, osteodystrophy, parathyroid hormone, pathogenesis, phosphates, vitamin D",

author = "Vincent Boima and Josephine Akpalu and Akosua Asomaning",

year = "2025",

month = jan,

day = "1",

doi = "10.1016/B978-0-443-33090-2.00019-9",

language = "English",

isbn = "9780443330919",

pages = "255--289",

booktitle = "RENAL FAILURE",

publisher = "Elsevier",

}

TY - CHAP

T1 - Renal osteodystrophy

T2 - new developments and challenges

AU - Boima, Vincent

AU - Akpalu, Josephine

AU - Asomaning, Akosua

PY - 2025/1/1

Y1 - 2025/1/1

N2 - Renal osteodystrophy is a bone ailment associated with or worsened by chronic kidney disease (CKD), resulting in fractures and further problems. CKD-mineral bone disorder (CKD-MBD) is a widely recognized term that characterizes a comprehensive systemic mineral and bone metabolism condition. Recent investigations have elucidated the involvement of several new variables in the pathophysiology of CKD-MBD, including wingless and integration 1 (Wnt) inhibitors, activin A, and myostatin. A bone biopsy is the definitive method for identifying CKD-MBD, whereas biomarkers like parathyroid hormone, calcium, phosphorus, alkaline phosphatase, and radiological imaging are advised for initial assessment. Innovative strategies for managing CKD-MBD designed to enhance outcomes have been established.

AB - Renal osteodystrophy is a bone ailment associated with or worsened by chronic kidney disease (CKD), resulting in fractures and further problems. CKD-mineral bone disorder (CKD-MBD) is a widely recognized term that characterizes a comprehensive systemic mineral and bone metabolism condition. Recent investigations have elucidated the involvement of several new variables in the pathophysiology of CKD-MBD, including wingless and integration 1 (Wnt) inhibitors, activin A, and myostatin. A bone biopsy is the definitive method for identifying CKD-MBD, whereas biomarkers like parathyroid hormone, calcium, phosphorus, alkaline phosphatase, and radiological imaging are advised for initial assessment. Innovative strategies for managing CKD-MBD designed to enhance outcomes have been established.

KW - Mineral bone disorder

KW - calcium

KW - imaging

KW - novel therapy

KW - osteodystrophy

KW - parathyroid hormone

KW - pathogenesis

KW - phosphates

KW - vitamin D

UR - https://www.scopus.com/pages/publications/105026832045

U2 - 10.1016/B978-0-443-33090-2.00019-9

DO - 10.1016/B978-0-443-33090-2.00019-9

M3 - Chapter

AN - SCOPUS:105026832045

SN - 9780443330919

SP - 255

EP - 289

BT - RENAL FAILURE

PB - Elsevier

ER -

Renal osteodystrophy: new developments and challenges

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this